Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Dermatitis atopic · Cancer

Sanofi-Aventis U.S

Sanofi-aventis Healthcare Pty Ltd

Sanofi-Aventis U.S clinical programs — 117 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
Status
Public
HQ
Bridgewater, USA
Employees
177
Programs
117
Drugs
148
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Sanofi-Aventis U.S projects

117 ClinicalTrials.gov programs sponsored by Sanofi-Aventis U.S.

Sanofi-Aventis U.S has 117 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

117 programs

Clinical programs

Page 1 of 3

  1. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  2. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  3. Duvakitug, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  4. Duvakitug, matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  5. EFC12522

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  6. EFC14462

    Sanofi-aventis Healthcare Pty Ltd

    Glycogen storage disease type II

    phase 3 small molecule active

    1 trial

  7. EFC14771

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  8. EFC15858

    Sanofi-aventis Healthcare Pty Ltd

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  9. EFC15951

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  10. EFC15992

    Sanofi-aventis Healthcare Pty Ltd

    Plasma cell myeloma

    phase 3 small molecule active

    1 trial

  11. EFC16158 - CARAT

    Sanofi-aventis Healthcare Pty Ltd

    Fabry’s disease

    phase 3 small molecule active

    1 trial

  12. EFC16521

    Sanofi-aventis Healthcare Pty Ltd

    Thrombotic Thrombocytopenic Purpura

    phase 3 small molecule active

    1 trial

  13. EFC16973

    Sanofi-aventis Healthcare Pty Ltd

    Pruritus

    phase 3 small molecule active

    1 trial

  14. EFC17045 - PERIDOT

    Sanofi-aventis Healthcare Pty Ltd

    Fabry Disease

    phase 3 small molecule active

    1 trial

  15. EFC17215 - LEAP2MONO

    Sanofi-aventis Healthcare Pty Ltd

    Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  16. EFC17236

    Sanofi-aventis Healthcare Pty Ltd

    Polyneuropathy, Inflammatory Demyelinating, Chronic

    phase 3 small molecule active

    1 trial

  17. EFC17359

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 other active

    1 trial

  18. EFC17360 - LUMINA 3

    Sanofi-aventis Healthcare Pty Ltd

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  19. EFC17559

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  20. EFC17560

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  21. EFC17561

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  22. EFC17599 - AQUA

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  23. EFC17600

    Sanofi-aventis Healthcare Pty Ltd

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  24. EFC17757

    Sanofi-aventis Healthcare Pty Ltd

    chronic graft versus host disease

    phase 3 small molecule active

    1 trial

  25. EFC17872

    Sanofi-aventis Healthcare Pty Ltd

    Blood and lymphatic diseases

    phase 3 small molecule active

    1 trial

  26. EFC17919A

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  27. EFC17919B

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  28. EFC18156

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

  29. EFC18554

    Sanofi-aventis Healthcare Pty Ltd

    Kidney transplant rejection

    phase 3 small molecule active

    1 trial

  30. Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  31. Itepekimab, Matched Placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  32. Itepekimab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  33. Itepekimab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  34. LTS17043

    Sanofi-aventis Healthcare Pty Ltd

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  35. LTS17043

    Sanofi-aventis Healthcare Pty Ltd

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  36. LTS17367

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  37. Matched placebo for product, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 3 small molecule active

    1 trial

  38. Matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system disseases

    phase 3 small molecule active

    1 trial

  39. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  40. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  41. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  42. PSK00010

    Sanofi-aventis Healthcare Pty Ltd

    Pneumococcal immunisation

    phase 3 small molecule active

    1 trial

  43. PSK04

    Sanofi-aventis Healthcare Pty Ltd

    Pneumococcal Immunization

    phase 3 small molecule active

    1 trial

  44. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  45. SAR439774, SAR439774

    Sanofi-aventis Healthcare Pty Ltd

    Hemophilia

    phase 3 small molecule active

    1 trial

  46. Teplizumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  47. VAD00004

    Sanofi-aventis Healthcare Pty Ltd

    Virus diseases

    phase 3 small molecule active

    1 trial

  48. matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Sanofi-Aventis U.S have?

117 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.